FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387647614> ?p ?o ?g. }

• W4387647614 endingPage "115691" @default.
• W4387647614 startingPage "115691" @default.
• W4387647614 abstract "Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) has been approved for treating multiple myeloma (MM). Some clinical studies reported suboptimal outcomes, including reduced cytotoxicity of CAR-T cells and tumor evasion through increased expression of programmed death-ligand 1 (PD-L1). To enhance CAR-T cell efficiency and overcome PD-L1-mediated T cell suppression, we developed anti-BCMA-CAR5-T cells equipped with three costimulatory domains and the ability to secrete anti-PD-L1 single-chain variable fragment (scFv) blockade molecules. Anti-BCMA-CAR4-T cells contained a fully human anti-BCMA scFv and three intracellular domains (CD28, 4-1BB, and CD27) joined with CD3ζ. Anti-BCMA-CAR5-T cells were generated by fusing anti-BCMA-CAR4 with anti-PD-L1 scFv. Both anti-BCMA-CAR4-T and anti-BCMA-CAR5-T cells demonstrated comparable antitumor activity against parental MM cells. However, at an effector-to-target ratio of 1:2, only anti-BCMA-CAR5-T cells maintained cytolytic activity against PD-L1 high MM cells, unlike anti-BCMA-CAR4 T cells. Anti-BCMA-CAR5-T cells were specifically activated by BCMA-expressing target cells, resulting in increased CAR-T cell proliferation, release of cytolytic mediators, and pro-inflammatory cytokines. Anti-BCMA-CAR5-T cells demonstrated specific cytotoxicity against BCMA-expressing target cells, leading to decreased target cell numbers, increased CAR-T cell numbers, and preserved CAR expression during antigenic re-stimulation. Interestingly, only anti-BCMA-CAR5-T cells showed reduced PD-1 receptor levels, which correlated with decreased PD-L1 expression on target cells. We successfully generated anti-BCMA-CAR5-T cells capable of secreting anti-PD-L1 scFv. These cells exhibited superior antitumor efficiency, proliferative capacity, and alleviated T-cell exhaustion against MM cells. Further investigation into the antitumor efficacy of anti-BCMA-CAR5-T cells is warranted in ex vivo and clinical research settings." @default.
• W4387647614 created "2023-10-15" @default.
• W4387647614 creator A5008629890 @default.
• W4387647614 creator A5009328108 @default.
• W4387647614 creator A5017565119 @default.
• W4387647614 creator A5028097176 @default.
• W4387647614 creator A5040102548 @default.
• W4387647614 creator A5073728432 @default.
• W4387647614 creator A5093065325 @default.
• W4387647614 date "2023-12-01" @default.
• W4387647614 modified "2023-10-18" @default.
• W4387647614 title "Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma" @default.
• W4387647614 cites W2003494920 @default.
• W4387647614 cites W2074286260 @default.
• W4387647614 cites W2086437355 @default.
• W4387647614 cites W2093463728 @default.
• W4387647614 cites W2102694800 @default.
• W4387647614 cites W2107598346 @default.
• W4387647614 cites W2118796952 @default.
• W4387647614 cites W2144728882 @default.
• W4387647614 cites W2198783967 @default.
• W4387647614 cites W2344653410 @default.
• W4387647614 cites W2504729294 @default.
• W4387647614 cites W2611210276 @default.
• W4387647614 cites W2795765610 @default.
• W4387647614 cites W2886131798 @default.
• W4387647614 cites W2889691274 @default.
• W4387647614 cites W2892311750 @default.
• W4387647614 cites W2899694188 @default.
• W4387647614 cites W2903062212 @default.
• W4387647614 cites W2942230814 @default.
• W4387647614 cites W2943335541 @default.
• W4387647614 cites W2991578820 @default.
• W4387647614 cites W3014583893 @default.
• W4387647614 cites W3045623523 @default.
• W4387647614 cites W3046016469 @default.
• W4387647614 cites W3120355176 @default.
• W4387647614 cites W3135346599 @default.
• W4387647614 cites W3137602932 @default.
• W4387647614 cites W3177496545 @default.
• W4387647614 cites W3193028765 @default.
• W4387647614 cites W4213299680 @default.
• W4387647614 cites W4281289906 @default.
• W4387647614 cites W4281788912 @default.
• W4387647614 cites W4283698909 @default.
• W4387647614 cites W4293149707 @default.
• W4387647614 cites W4293536418 @default.
• W4387647614 cites W4294219068 @default.
• W4387647614 cites W4306773867 @default.
• W4387647614 cites W4312066549 @default.
• W4387647614 cites W4319440830 @default.
• W4387647614 cites W4321373696 @default.
• W4387647614 doi "https://doi.org/10.1016/j.biopha.2023.115691" @default.
• W4387647614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37844355" @default.
• W4387647614 hasPublicationYear "2023" @default.
• W4387647614 type Work @default.
• W4387647614 citedByCount "0" @default.
• W4387647614 crossrefType "journal-article" @default.
• W4387647614 hasAuthorship W4387647614A5008629890 @default.
• W4387647614 hasAuthorship W4387647614A5009328108 @default.
• W4387647614 hasAuthorship W4387647614A5017565119 @default.
• W4387647614 hasAuthorship W4387647614A5028097176 @default.
• W4387647614 hasAuthorship W4387647614A5040102548 @default.
• W4387647614 hasAuthorship W4387647614A5073728432 @default.
• W4387647614 hasAuthorship W4387647614A5093065325 @default.
• W4387647614 hasBestOaLocation W43876476141 @default.
• W4387647614 hasConcept C147483822 @default.
• W4387647614 hasConcept C148125776 @default.
• W4387647614 hasConcept C153911025 @default.
• W4387647614 hasConcept C154317977 @default.
• W4387647614 hasConcept C167672396 @default.
• W4387647614 hasConcept C185592680 @default.
• W4387647614 hasConcept C202751555 @default.
• W4387647614 hasConcept C203014093 @default.
• W4387647614 hasConcept C2776090121 @default.
• W4387647614 hasConcept C3875195 @default.
• W4387647614 hasConcept C502942594 @default.
• W4387647614 hasConcept C55493867 @default.
• W4387647614 hasConcept C67662055 @default.
• W4387647614 hasConcept C73588182 @default.
• W4387647614 hasConcept C86803240 @default.
• W4387647614 hasConcept C8891405 @default.
• W4387647614 hasConcept C95444343 @default.
• W4387647614 hasConceptScore W4387647614C147483822 @default.
• W4387647614 hasConceptScore W4387647614C148125776 @default.
• W4387647614 hasConceptScore W4387647614C153911025 @default.
• W4387647614 hasConceptScore W4387647614C154317977 @default.
• W4387647614 hasConceptScore W4387647614C167672396 @default.
• W4387647614 hasConceptScore W4387647614C185592680 @default.
• W4387647614 hasConceptScore W4387647614C202751555 @default.
• W4387647614 hasConceptScore W4387647614C203014093 @default.
• W4387647614 hasConceptScore W4387647614C2776090121 @default.
• W4387647614 hasConceptScore W4387647614C3875195 @default.
• W4387647614 hasConceptScore W4387647614C502942594 @default.
• W4387647614 hasConceptScore W4387647614C55493867 @default.
• W4387647614 hasConceptScore W4387647614C67662055 @default.
• W4387647614 hasConceptScore W4387647614C73588182 @default.
• W4387647614 hasConceptScore W4387647614C86803240 @default.

• next